Jack Higgins Sells 9,438 Shares of Immunome (NASDAQ:IMNM) Stock

Immunome, Inc. (NASDAQ:IMNM) insider Jack Higgins sold 9,438 shares of the business’s stock in a transaction dated Thursday, April 2nd. The shares were sold at an average price of $21.64, for a total transaction of $204,238.32. Following the completion of the sale, the insider directly owned 22,000 shares of the company’s stock, valued at $476,080. This represents a 30.02% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Immunome Price Performance

Shares of NASDAQ:IMNM opened at $21.84 on Friday. Immunome, Inc. has a 12-month low of $5.15 and a 12-month high of $27.65. The company’s 50 day moving average price is $22.34 and its two-hundred day moving average price is $19.29. The firm has a market cap of $2.47 billion, a PE ratio of -9.02 and a beta of 2.13.

Immunome (NASDAQ:IMNM) last released its quarterly earnings results on Tuesday, March 3rd. The company reported ($0.75) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.65) by ($0.10). On average, research analysts expect that Immunome, Inc. will post -2.21 EPS for the current year.

Analysts Set New Price Targets

Several analysts have recently issued reports on the company. HC Wainwright began coverage on Immunome in a report on Thursday, February 12th. They set a “buy” rating and a $40.00 target price on the stock. Leerink Partners set a $40.00 price target on Immunome in a research note on Monday, December 15th. Craig Hallum increased their price objective on shares of Immunome from $33.00 to $36.00 and gave the stock a “buy” rating in a research note on Wednesday, March 4th. Wall Street Zen downgraded shares of Immunome from a “hold” rating to a “sell” rating in a research note on Saturday, March 7th. Finally, Lake Street Capital boosted their target price on shares of Immunome from $22.00 to $32.00 and gave the company a “buy” rating in a research report on Tuesday, December 16th. Ten analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $33.45.

Institutional Investors Weigh In On Immunome

Large investors have recently modified their holdings of the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in shares of Immunome by 44.4% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 46,821 shares of the company’s stock worth $316,000 after buying an additional 14,398 shares in the last quarter. Creative Planning acquired a new stake in Immunome in the second quarter valued at about $167,000. Swiss National Bank boosted its stake in Immunome by 3.8% in the second quarter. Swiss National Bank now owns 132,800 shares of the company’s stock valued at $1,235,000 after buying an additional 4,800 shares in the last quarter. Rhumbline Advisers grew its position in Immunome by 22.0% in the second quarter. Rhumbline Advisers now owns 108,414 shares of the company’s stock valued at $1,008,000 after acquiring an additional 19,526 shares during the last quarter. Finally, Lido Advisors LLC grew its position in Immunome by 11.5% in the second quarter. Lido Advisors LLC now owns 59,085 shares of the company’s stock valued at $549,000 after acquiring an additional 6,085 shares during the last quarter. Institutional investors and hedge funds own 44.58% of the company’s stock.

About Immunome

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.